Cells called alveolar macrophages help clear the surfactant and stop it from building up. In most cases of pulmonary alveolar proteinosis in adults, the cause is thought to be a problem with ...

PULMONARY alveolar microlithiasis is a rare and extraordinary disease in which microscopic stones are found within the pulmonary alveoli. The lungs, which are heavy and stony hard, cut with the ...

Texas, USA-based clinical-stage biopharma Savara (Nasdaq: SVRA) on Tuesday announced that the company received a refuse to ...

Despite hiring a commercial chief and sponsoring disease awareness efforts last year, Savara will have to wait a while longer ...

The Food and Drug Administration has rejected an application filed by Langhorne-based Savara for its new drug candidate ...

Molbreevi – a new inhaled formulation of the well-established and off-patent white blood cell stimulator molgramostim – is ...

In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating ...

SO, STEPHEN, AT THE UNIVERSITY OF MARYLAND MEDICAL CENTER. SO ADRIAN HAS AN OFTEN LUNG DISEASE CALLED AUTOIMMUNE PULMONARY ALVEOLAR PROTEIN. OSIS PUTS SIMPLY PULMONARY ALVEOLAR PROTO GNOSIS OR PAP ...

Savara (SVRA) stock in focus as FDA issues a refusal to file letter regarding its marketing application for its lead drug, ...

The Effects of Molgramostim on Respiratory Health-related Quality of Life and Patient-reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Molgramostim showed ...

Poster Board 701: "Healthcare Burden of Pulmonary Alveolar Proteinosis" presented by E. Lee, M.D., Ph.D.; sponsored by Savara Inc. Presented data from a retrospective cohort analysis using a ...

Savara plans to request a Type A meeting with the FDA within the next 30 days. It is currently generating the data requested by the FDA, and expects to resubmit its application in the fourth quarter ...